Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Type of study
Language
Year range
1.
MEAJO-Middle East African Journal of Ophthalmology. 2010; 17 (3): 281-284
in English | IMEMR | ID: emr-123607

ABSTRACT

Despite initial concerns regarding systemic complications, the use of intravitreal antivascular endothelial growth factor [anti-VEGF] agents for ocular disease is rapidly expanding worldwide, in terms of both the number of patients injected and its indications. To our knowledge, there are no cases in the literature reporting erectile dysfunction following the use of intravitreal bevacizumab. We postulate an organic mechanism for impaired erectile function due to systemically absorbed intravitreal bevacizumab. We describe a case of erectile dysfunction following intravitreal bevacizumab administration. Color fundus photos, fluorescein angiogram and optical coherence tomography images are presented. A 40-year-old male underwent intravitreal bevacizumab therapy for macular edema secondary to a branch retinal vein occlusion. He subsequently developed transient erectile dysfunction after each of his two bevacizumab injections. His only comorbidity was mild hypertension. Erectile dysfunction may be a side effect of intravitreal bevacizumab. The erectile dysfunction could be organic and/or psychogenic in etiology


Subject(s)
Humans , Male , Antibodies, Monoclonal/adverse effects , Vascular Endothelial Growth Factor A/adverse effects , Vitreous Body , Tomography, Optical Coherence , Fluorescein Angiography , Macular Edema , Retinal Vein Occlusion
SELECTION OF CITATIONS
SEARCH DETAIL